How would you describe your company in a single tweet?
Lumosa is an organization of inspired medical professionals whose mission is to enrich patients’ lives through pioneering technology to fulfill unmet medical needs in the field of neurological disease, especially stroke. #strokeawareness; #neuroleadership; #stroke; #strokerecovery
How did it all start and why?
Stroke is a disease with significant global unmet medical need. There are 15 million people worldwide who suffer a stroke each year, and it is the second leading cause of death for people above the age of 60. Currently there is only one standard medication for stroke, and it can only be effectively administered to patients within 4.5hr after stroke onset. Therefore, 80% of stroke patients remain with no other treatment options or without desired outcomes. Clearly additional stroke treatments are greatly needed. Unfortunately, drug trial failures in the last two decades- mostly due to brain bleeding or lack of proven efficacy – has limited R&D to those rare companies committed to the stroke community. As the overall average age of the global population increases, Lumsoa realizes the urgency and is committed to be a global innovator in stroke. LT3001 represents a completely novel drug design in stroke treatment — combining thrombolytic and neuroprotective properties into a single molecule which may confer unique efficacy and safety properties permitting an extended treatment window without increasing the risk of brain bleeding. We believe LT3001 has the potential to benefit most of the stroke patients therefore become a global standard of care therapy.
What have you achieved so far?
With a group of professionals fully committed to translational research and clinical development, Lumosa acquired the global rights to LT3001 from Beijing Capital Medical University and will develop the molecule from bench to human clinical trials. Lumosa recently announced positive results from its phase 2a clinical trial of LT3001. These data successfully demonstrated that LT3001 would not increase the risk of brain bleeding and showed a very encouraging efficacy trend for patients within 24hr stroke onset. Shanghai Pharmaceutical Holding has acquired rights to LT3001 in China and will continue developing LT3001 for the later phase of clinical trials in China. Lumosa also discovered and developed the world’s first week-long extended-release analgesic injection for post-operative pain, LT1001. LT1001 was launched in Taiwan and Singapore, and the approvals in Thailand, Malaysia, Korea, and Ukraine are expected in 2021 or 2022. Further, Lumosa is also researching LT5001, a new drug under development for the treatment of uremic pruritus. In the western world, there is only one approved medication, and it is limited to patients undergoing dialysis. LT5001 is the first topical medication therefore avoiding concern of systemic toxicity and can be applied to either dialysis or non-dialysis patient populations.
What do you plan to achieve in the next 2-3 years?
In parallel to the successful outcomes of Lumosa’s Phase 2 study, Lumosa will continue to conduct multiple global LT3001 clinical trials to elucidate the benefits on stroke patients left with no treatment options. Lumosa will engage with global partners for later phase development to accelerate the development program and increase the feasibility of technical success. We believe LT3001 has the potential to be an effective and safe medication which could apply to most of the stroke patients therefore represent a preferable therapeutic option for physicians treating stroke.
How will you use your recent funding round?
Lumosa is a publicly listed company (TWO. 6535) in Taiwan with adequate funding for supporting its LT3001 development programs globally.
